Cargando…

Poor overall survival in hyperhaploid multiple myeloma is defined by double-hit bi-allelic inactivation of TP53

Hyperhaploid multiple myeloma is a rare numerical aberration group defined by a range of 24-34 chromosomes, which is associated with a poor prognosis with a 5-year survival rate of 23%. Hyperhaploid patient samples (n=8) were sequenced and copy number and mutations identified. Samples had a median o...

Descripción completa

Detalles Bibliográficos
Autores principales: Ashby, Cody, Tytarenko, Ruslana G., Wang, Yan, Weinhold, Niels, Johnson, Sarah K., Bauer, Michael, Wardell, Christopher P., Schinke, Carolina, Thanendrarajan, Sharmilan, Zangari, Mauricio, van Rhee, Frits, Davies, Faith E., Sawyer, Jeffrey R., Morgan, Gareth J., Walker, Brian A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366829/
https://www.ncbi.nlm.nih.gov/pubmed/30774775
http://dx.doi.org/10.18632/oncotarget.26589
_version_ 1783393673141026816
author Ashby, Cody
Tytarenko, Ruslana G.
Wang, Yan
Weinhold, Niels
Johnson, Sarah K.
Bauer, Michael
Wardell, Christopher P.
Schinke, Carolina
Thanendrarajan, Sharmilan
Zangari, Mauricio
van Rhee, Frits
Davies, Faith E.
Sawyer, Jeffrey R.
Morgan, Gareth J.
Walker, Brian A.
author_facet Ashby, Cody
Tytarenko, Ruslana G.
Wang, Yan
Weinhold, Niels
Johnson, Sarah K.
Bauer, Michael
Wardell, Christopher P.
Schinke, Carolina
Thanendrarajan, Sharmilan
Zangari, Mauricio
van Rhee, Frits
Davies, Faith E.
Sawyer, Jeffrey R.
Morgan, Gareth J.
Walker, Brian A.
author_sort Ashby, Cody
collection PubMed
description Hyperhaploid multiple myeloma is a rare numerical aberration group defined by a range of 24-34 chromosomes, which is associated with a poor prognosis with a 5-year survival rate of 23%. Hyperhaploid patient samples (n=8) were sequenced and copy number and mutations identified. Samples had a median of 13 monosomies (range 12-14), which in general were those not associated with trisomies in hyperdiploid samples. The chromosomes traditionally trisomic in hyperdiploid myeloma were disomic in hyperhaploid myeloma with retention of heterodisomy. We examined the hyperhaploid samples for frequently mutated genes and found that 8/8 (100%) hyperhaploid samples had a mutation in TP53, exceeding the overall rate of mutation in newly diagnosed patients (5.5%), indicating an oncogenic dependency in this group. All samples with TP53 mutation also had monosomy of chromosome 17, indicating bi-allelic inactivation of TP53. As such, this high risk group is part of double-hit myeloma.
format Online
Article
Text
id pubmed-6366829
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-63668292019-02-15 Poor overall survival in hyperhaploid multiple myeloma is defined by double-hit bi-allelic inactivation of TP53 Ashby, Cody Tytarenko, Ruslana G. Wang, Yan Weinhold, Niels Johnson, Sarah K. Bauer, Michael Wardell, Christopher P. Schinke, Carolina Thanendrarajan, Sharmilan Zangari, Mauricio van Rhee, Frits Davies, Faith E. Sawyer, Jeffrey R. Morgan, Gareth J. Walker, Brian A. Oncotarget Research Paper Hyperhaploid multiple myeloma is a rare numerical aberration group defined by a range of 24-34 chromosomes, which is associated with a poor prognosis with a 5-year survival rate of 23%. Hyperhaploid patient samples (n=8) were sequenced and copy number and mutations identified. Samples had a median of 13 monosomies (range 12-14), which in general were those not associated with trisomies in hyperdiploid samples. The chromosomes traditionally trisomic in hyperdiploid myeloma were disomic in hyperhaploid myeloma with retention of heterodisomy. We examined the hyperhaploid samples for frequently mutated genes and found that 8/8 (100%) hyperhaploid samples had a mutation in TP53, exceeding the overall rate of mutation in newly diagnosed patients (5.5%), indicating an oncogenic dependency in this group. All samples with TP53 mutation also had monosomy of chromosome 17, indicating bi-allelic inactivation of TP53. As such, this high risk group is part of double-hit myeloma. Impact Journals LLC 2019-01-22 /pmc/articles/PMC6366829/ /pubmed/30774775 http://dx.doi.org/10.18632/oncotarget.26589 Text en Copyright: © 2019 Ashby et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Ashby, Cody
Tytarenko, Ruslana G.
Wang, Yan
Weinhold, Niels
Johnson, Sarah K.
Bauer, Michael
Wardell, Christopher P.
Schinke, Carolina
Thanendrarajan, Sharmilan
Zangari, Mauricio
van Rhee, Frits
Davies, Faith E.
Sawyer, Jeffrey R.
Morgan, Gareth J.
Walker, Brian A.
Poor overall survival in hyperhaploid multiple myeloma is defined by double-hit bi-allelic inactivation of TP53
title Poor overall survival in hyperhaploid multiple myeloma is defined by double-hit bi-allelic inactivation of TP53
title_full Poor overall survival in hyperhaploid multiple myeloma is defined by double-hit bi-allelic inactivation of TP53
title_fullStr Poor overall survival in hyperhaploid multiple myeloma is defined by double-hit bi-allelic inactivation of TP53
title_full_unstemmed Poor overall survival in hyperhaploid multiple myeloma is defined by double-hit bi-allelic inactivation of TP53
title_short Poor overall survival in hyperhaploid multiple myeloma is defined by double-hit bi-allelic inactivation of TP53
title_sort poor overall survival in hyperhaploid multiple myeloma is defined by double-hit bi-allelic inactivation of tp53
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366829/
https://www.ncbi.nlm.nih.gov/pubmed/30774775
http://dx.doi.org/10.18632/oncotarget.26589
work_keys_str_mv AT ashbycody pooroverallsurvivalinhyperhaploidmultiplemyelomaisdefinedbydoublehitbiallelicinactivationoftp53
AT tytarenkoruslanag pooroverallsurvivalinhyperhaploidmultiplemyelomaisdefinedbydoublehitbiallelicinactivationoftp53
AT wangyan pooroverallsurvivalinhyperhaploidmultiplemyelomaisdefinedbydoublehitbiallelicinactivationoftp53
AT weinholdniels pooroverallsurvivalinhyperhaploidmultiplemyelomaisdefinedbydoublehitbiallelicinactivationoftp53
AT johnsonsarahk pooroverallsurvivalinhyperhaploidmultiplemyelomaisdefinedbydoublehitbiallelicinactivationoftp53
AT bauermichael pooroverallsurvivalinhyperhaploidmultiplemyelomaisdefinedbydoublehitbiallelicinactivationoftp53
AT wardellchristopherp pooroverallsurvivalinhyperhaploidmultiplemyelomaisdefinedbydoublehitbiallelicinactivationoftp53
AT schinkecarolina pooroverallsurvivalinhyperhaploidmultiplemyelomaisdefinedbydoublehitbiallelicinactivationoftp53
AT thanendrarajansharmilan pooroverallsurvivalinhyperhaploidmultiplemyelomaisdefinedbydoublehitbiallelicinactivationoftp53
AT zangarimauricio pooroverallsurvivalinhyperhaploidmultiplemyelomaisdefinedbydoublehitbiallelicinactivationoftp53
AT vanrheefrits pooroverallsurvivalinhyperhaploidmultiplemyelomaisdefinedbydoublehitbiallelicinactivationoftp53
AT daviesfaithe pooroverallsurvivalinhyperhaploidmultiplemyelomaisdefinedbydoublehitbiallelicinactivationoftp53
AT sawyerjeffreyr pooroverallsurvivalinhyperhaploidmultiplemyelomaisdefinedbydoublehitbiallelicinactivationoftp53
AT morgangarethj pooroverallsurvivalinhyperhaploidmultiplemyelomaisdefinedbydoublehitbiallelicinactivationoftp53
AT walkerbriana pooroverallsurvivalinhyperhaploidmultiplemyelomaisdefinedbydoublehitbiallelicinactivationoftp53